FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048100812> ?p ?o ?g. }

• W3048100812 endingPage "76.e22" @default.
• W3048100812 startingPage "76.e15" @default.
• W3048100812 abstract "There is no current standard of care for patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after neoadjuvant chemotherapy and surgical resection or for those who cannot receive or decline cisplatin-based perioperative chemotherapy. Understanding current, real-world treatment patterns may help inform decisions from clinical, research, and population health management perspectives. We examined real-world treatment patterns, survival outcomes, and prognostic factors among Medicare beneficiaries with high-risk MIUC who did not receive adjuvant treatment after surgical resection. We identified patients with high-risk MIUC in the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database who underwent surgical resection (radical cystectomy and/or radical nephroureterectomy). Eligible patients had indicators of high-risk MIUC and surgical resection between 2001 and 2013. Demographic and clinical characteristics, including comorbidities, American Joint Commission on Cancer (AJCC) stage, tumor stage/grade and nodal status, and distribution of neoadjuvant treatment by the year of surgical resection were evaluated. Overall survival (OS) and disease-free survival (DFS) were assessed for the full cohort and by subgroups using Kaplan-Meier survival analysis. Adjusted Cox proportional hazards models were used to evaluate patient demographics and clinical characteristics associated with OS and DFS. A total of 665 patients were included in the analysis, with a mean age of 75.5 years; most were men (61%) and had AJCC stage IIIA disease (69%). Neoadjuvant treatment increased over the entire study period, both overall (from 12% to 46%) and cisplatin based (from 5% to 38%). Median OS for the entire cohort was 23.1 months (95% confidence interval: 18, 27); median DFS was 13.5 months (95% confidence interval: 11.3, 16.8). AJCC stage IIIB/IVA was the most significant predictor of poor prognosis for both OS and DFS, followed by non-white race and comorbidity burden. The prognosis for high-risk patients with MIUC remains poor, with significant risk of mortality within 2 years of radical cystectomy despite increasing use of neoadjuvant treatment. Unmet treatment needs persist for this difficult-to-treat patient population despite the increasing use of cisplatin-based neoadjuvant chemotherapy." @default.
• W3048100812 created "2020-08-13" @default.
• W3048100812 creator A5014666581 @default.
• W3048100812 creator A5020030529 @default.
• W3048100812 creator A5026717218 @default.
• W3048100812 creator A5039495553 @default.
• W3048100812 creator A5049657362 @default.
• W3048100812 creator A5052069448 @default.
• W3048100812 creator A5063684760 @default.
• W3048100812 creator A5081569621 @default.
• W3048100812 creator A5083226225 @default.
• W3048100812 date "2021-01-01" @default.
• W3048100812 modified "2023-10-13" @default.
• W3048100812 title "“Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma" @default.
• W3048100812 cites W1974722941 @default.
• W3048100812 cites W1975918912 @default.
• W3048100812 cites W2041435757 @default.
• W3048100812 cites W2084075250 @default.
• W3048100812 cites W2103561213 @default.
• W3048100812 cites W2108145868 @default.
• W3048100812 cites W2110921920 @default.
• W3048100812 cites W2113156769 @default.
• W3048100812 cites W2128042367 @default.
• W3048100812 cites W2136108195 @default.
• W3048100812 cites W2151278059 @default.
• W3048100812 cites W2166453367 @default.
• W3048100812 cites W2336213711 @default.
• W3048100812 cites W2604655222 @default.
• W3048100812 cites W2609787832 @default.
• W3048100812 cites W2737546054 @default.
• W3048100812 cites W2795922342 @default.
• W3048100812 cites W2807001445 @default.
• W3048100812 cites W2888501871 @default.
• W3048100812 cites W2888571497 @default.
• W3048100812 cites W2900969149 @default.
• W3048100812 cites W2942805854 @default.
• W3048100812 doi "https://doi.org/10.1016/j.urolonc.2020.07.011" @default.
• W3048100812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32778476" @default.
• W3048100812 hasPublicationYear "2021" @default.
• W3048100812 type Work @default.
• W3048100812 sameAs 3048100812 @default.
• W3048100812 citedByCount "6" @default.
• W3048100812 countsByYear W30481008122021 @default.
• W3048100812 countsByYear W30481008122023 @default.
• W3048100812 crossrefType "journal-article" @default.
• W3048100812 hasAuthorship W3048100812A5014666581 @default.
• W3048100812 hasAuthorship W3048100812A5020030529 @default.
• W3048100812 hasAuthorship W3048100812A5026717218 @default.
• W3048100812 hasAuthorship W3048100812A5039495553 @default.
• W3048100812 hasAuthorship W3048100812A5049657362 @default.
• W3048100812 hasAuthorship W3048100812A5052069448 @default.
• W3048100812 hasAuthorship W3048100812A5063684760 @default.
• W3048100812 hasAuthorship W3048100812A5081569621 @default.
• W3048100812 hasAuthorship W3048100812A5083226225 @default.
• W3048100812 hasBestOaLocation W30481008121 @default.
• W3048100812 hasConcept C121608353 @default.
• W3048100812 hasConcept C126322002 @default.
• W3048100812 hasConcept C141071460 @default.
• W3048100812 hasConcept C143998085 @default.
• W3048100812 hasConcept C146357865 @default.
• W3048100812 hasConcept C151730666 @default.
• W3048100812 hasConcept C2775910329 @default.
• W3048100812 hasConcept C2778292576 @default.
• W3048100812 hasConcept C2780352672 @default.
• W3048100812 hasConcept C31174226 @default.
• W3048100812 hasConcept C50382708 @default.
• W3048100812 hasConcept C530470458 @default.
• W3048100812 hasConcept C71924100 @default.
• W3048100812 hasConcept C72563966 @default.
• W3048100812 hasConcept C86803240 @default.
• W3048100812 hasConceptScore W3048100812C121608353 @default.
• W3048100812 hasConceptScore W3048100812C126322002 @default.
• W3048100812 hasConceptScore W3048100812C141071460 @default.
• W3048100812 hasConceptScore W3048100812C143998085 @default.
• W3048100812 hasConceptScore W3048100812C146357865 @default.
• W3048100812 hasConceptScore W3048100812C151730666 @default.
• W3048100812 hasConceptScore W3048100812C2775910329 @default.
• W3048100812 hasConceptScore W3048100812C2778292576 @default.
• W3048100812 hasConceptScore W3048100812C2780352672 @default.
• W3048100812 hasConceptScore W3048100812C31174226 @default.
• W3048100812 hasConceptScore W3048100812C50382708 @default.
• W3048100812 hasConceptScore W3048100812C530470458 @default.
• W3048100812 hasConceptScore W3048100812C71924100 @default.
• W3048100812 hasConceptScore W3048100812C72563966 @default.
• W3048100812 hasConceptScore W3048100812C86803240 @default.
• W3048100812 hasFunder F4320309432 @default.
• W3048100812 hasIssue "1" @default.
• W3048100812 hasLocation W30481008121 @default.
• W3048100812 hasOpenAccess W3048100812 @default.
• W3048100812 hasPrimaryLocation W30481008121 @default.
• W3048100812 hasRelatedWork W2014265311 @default.
• W3048100812 hasRelatedWork W2122875447 @default.
• W3048100812 hasRelatedWork W2393019419 @default.
• W3048100812 hasRelatedWork W2595618663 @default.
• W3048100812 hasRelatedWork W2910048357 @default.
• W3048100812 hasRelatedWork W2923057472 @default.
• W3048100812 hasRelatedWork W3016448636 @default.
• W3048100812 hasRelatedWork W3029820510 @default.

• next